

GUIDE FOR PRESCRIBERS

This guide contains the checklist of actions to be completed before and after treatment initiation. This checklist is part of the CERDELGA Risk Management Plan and is to be used in conjunction with the CERDELGA Product Information.

Guide for prescribers

CERDELGA® (eliglustat) is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1).¹

This guide has been developed as part of the CERDELGA Risk Management Plan (RMP) and is intended for physicians who initiate and supervise CERDELGA treatment. It is intended to improve the use of CERDELGA by positively influencing appropriate actions.

It contains:

- The checklist of actions to be completed before and after treatment initiation. This checklist is part of the CERDELGA Risk Management Plan and is to be used in conjunction with the CERDELGA Product Information.
- Information on CYP2D6 genotyping assessment.
- Information on reporting suspected adverse reactions.

In addition, a *Patient Alert Card* has been developed as part of the RMP for patients initiated on CERDELGA treatment. If needed, cards are available upon request from Medical Information (1800 818 806 or Medinfo.australia@sanofi.com). This card is a liaison tool to inform any healthcare professionals who are treating patients receiving CERDELGA about drug-drug interactions that should be considered before prescription or delivery of any additional medicinal products, including herbal products. The patient (or caregivers when appropriate) should be told to carry this card at all times and show it to any healthcare professional who may be prescribing or recommending additional medicinal products. Moreover, it contains information to remind the patient about the risk of self-medication and consumption of grapefruit products. An example of this card is attached in **Appendix 1**. For more information on CERDELGA, please refer to the full Product Information or contact Sanofi Medical Information (1800 818 806 or Medinfo.australia@sanofi.com).

1 Prescriber Checklist

1. Before treatment initiation, verify that the patient is suitable for CERDELGA treatment

- Confirm the patient's eligibility for CERDELGA in four steps:
 - The patient must be an adult with Gaucher disease type 1
 - The patient should be genotyped to ensure they are a CYP2D6 poor (PM), intermediate (IM) or extensive (EM) metaboliser
 - Refer to the table below to assess the appropriate dose based on the patient's CYP2D6 phenotype defined in the above step and their concomitant medication use, and hepatic and renal status
 - The patient must not have pre-existing cardiac conditions; refer to the full Product Information for specific details

For additional information, including a non-exhaustive list of example concomitant medications, please refer to the full Product Information.

CYP2D6 phenotype	Extensive metaboliser (EM)	Intermediate metaboliser (IM)	Poor metaboliser (PM)
Standard dosing	84 mg BID	84 mg BID	84 mg OD
Concomitant use of CYP2D6 and/or CYP3A inhibitors, which increase plasma concentrations of eliglustat			
Strong or moderate CYP2D6 inhibitors AND strong or moderate CYP3A inhibitors	Contraindicated	Contraindicated	See below for strong or moderate CYP3A inhibitors
Strong CYP2D6 inhibitors	84 mg OD	84 mg OD	84 mg OD
Moderate CYP2D6 inhibitors	84 mg BID with caution	84 mg BID with caution	84 mg OD
Strong CYP3A inhibitors	84 mg BID with caution	84 mg BID with caution	Contraindicated
Moderate CYP3A inhibitors	84 mg BID with caution	84 mg BID with caution	Not recommended
Weak CYP3A inhibitors	84 mg BID	84 mg BID	84 mg OD with caution
Grapefruit products fall under the category of strong CYP3A inhibitors and can increase plasma concentrations of eliglustat. Consumption of grapefruit or its juice should be avoided.			

BID, twice daily; OD once daily.

CYP2D6 phenotype	Extensive metaboliser (EM)	Intermediate metaboliser (IM)	Poor metaboliser (PM)
Concomitant use of strong CYP3A inducers, which decrease plasma concentrations of eliglustat			
Strong CYP3A inducers	Not recommended	Not recommended	Not recommended
Concomitant use of agents whose exposure may be increased by eliglustat			
P-gp substrates	Lower doses of substances which are P-gp substrates may be required		
CYP2D6 substrates	Lower doses of medicinal products that are CYP2D6 substrates may be required		
Patients with hepatic impairment			
Mild impairment	84 mg BID	Contraindicated	Contraindicated
Mild impairment AND use of weak CYP2D6 inhibitor OR any CYP3A inhibitor	84 mg OD	Contraindicated	Contraindicated
Mild impairment AND use of strong or moderate CYP2D6 inhibitor	Contraindicated	Contraindicated	Contraindicated
Moderate impairment	Contraindicated	Contraindicated	Contraindicated
Moderate impairment AND use of strong or moderate CYP2D6 inhibitor	Contraindicated	Contraindicated	Contraindicated
Severe impairment	Contraindicated	Contraindicated	Contraindicated
Patients with renal impairment			
Mild, moderate or severe impairment	84 mg BID	Not recommended	Not recommended
End stage renal disease (ESRD)	Not recommended	Not recommended	Not recommended

BID, twice daily; OD once daily.

2. Patient education

- The patient has been informed about the drug-drug interactions that could occur with CERDELGA and the importance of informing all healthcare professionals about current medications and treatment
- The patient has been informed about the risk of self-medication and consumption of grapefruit products
- The *Patient Alert Card* has been provided and its use has been explained to the patient (i.e. you have discussed the importance of showing the card to all their healthcare professionals)

AT PATIENT FOLLOW-UP, CHECK THE FOLLOWING

3. Medical conditions

- Inquire about any changes in medical history or new medications since last visit (including over-the-counter medications or herbal products) and use of grapefruit products
- Check for suspected adverse reactions

4. Patient education

- Check for appropriate use of the *Patient Alert Card*
- Remind the patient about the risk of self-medication and consumption of grapefruit products

2 Predicted Cytochrome P450 2D6 Metabolic Activity

CERDELGA is to be used only in patients who have a predicted CYP2D6 poor, intermediate or extensive metaboliser phenotype based on genotyping. **Determination of the patient's CYP2D6 phenotype prior to starting CERDELGA is required.**

Genotyping to determine the patient's CYP2D6 phenotype is to be performed using an established genetic laboratory test that is able to detect a specific set of CYP2D6 alleles[†] with adequate accuracy, sensitivity and specificity in order to ensure consistent identification of CYP2D6 metaboliser status. DNA for genotyping can be collected using a cheek swab or a blood sample.

Only qualified experts should be involved in the interpretation of the genotyping data. To minimise the risk of error, it is recommended that the results of the CYP2D6 phenotype align with the terminology used in the full Product Information (i.e. poor, intermediate or extensive metaboliser).

For patients who meet eligibility criteria defined in the full Product Information, Sanofi can provide laboratory services for CYP2D6 metaboliser genotyping. For more information about this service contact Medical information (1800 818 806).

[†]At least the following alleles: *2, *3, *4, *5, *7, *8, *9, *14A, *14B, *17, *41, *1XN, *2XN, *4XN, *10XN, *17XN, *41XN, *39.


3 Reporting of suspected adverse reactions

Reporting any suspected adverse reactions is important for the continued monitoring of the benefit/risk balance of all medicinal products.

You are asked to report any suspected adverse reactions via the TGA at www.tga.gov.au/reporting-problems or directly to Sanofi at ae@sanofi.com or call on (02) 8666 2123.

4 If you want more information about CERDELGA

Please review the full Product Information before prescribing, available from <https://qr.medsinfo.com.au/tx/sw.cfm?h=swccerde> or by calling 1800 818 806.



PATIENT ALERT CARD

Please carry this card with you at all times and show it to any healthcare professional to inform them about your current treatment with CERDELGA.

- Do not start any new prescription medication, over-the-counter medication or herbal product without telling your doctor or pharmacist¹
- Do not consume grapefruit or grapefruit products¹

sanofi

Patient's name: _____

Date CERDELGA first prescribed: _____


Centre name: _____

Treating doctor's name: _____

Treating doctor's phone number: _____

CYP2D6 Metaboliser Status:

Poor Metaboliser Intermediate Metaboliser Extensive Metaboliser



Information for healthcare professionals²

CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1). For additional information, please refer to the full Product Information or contact Medical Information (1800 818 806 or Medinfo.australia@sanofi.com)

Extensive Metaboliser (EM) and Intermediate Metaboliser (IM) patients:

- CERDELGA must not be used in EM and IM patients:
 - taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
 - CERDELGA must not be used in EM or IM patients with any degree of hepatic impairment except in EM patients with mild hepatic impairment not being treated with a strong or moderate CYP2D6 inhibitor
 - CERDELGA is not recommended to be used:
 - in EM or IM patients with end stage renal disease or in IM patients with mild, moderate or severe renal impairment
 - in combination with strong CYP3A inducers
- CERDELGA should be used with caution in combination with:
 - a moderate CYP2D6 inhibitor
 - a strong or moderate CYP3A inhibitor
 - a P-glycoprotein (P-gp) or a CYP2D6 substrate (lower doses of such drugs may be required)
- CERDELGA dose should be reduced to 84 mg ONCE a day:
 - in EM or IM patients when concomitantly treated with a strong CYP2D6 inhibitor
 - in EM patients with mild hepatic impairment treated with a weak CYP2D6 inhibitor or any CYP3A inhibitor

Poor Metaboliser (PM) patients:

- CERDELGA must not be used:
 - in combination with a strong CYP3A inhibitor
 - in PM patients with any degree of hepatic impairment
- CERDELGA is not recommended to be used:
 - in combination with a moderate CYP3A inhibitor or a strong CYP3A inducer
 - in PM patients with end stage renal disease or in PM patients with mild, moderate or severe renal impairment
- CERDELGA should be used with caution in combination with:
 - a weak CYP3A inhibitor
 - a P-gp or a CYP2D6 substrate (lower doses of such drugs may be required)

REFERENCES: 1. Cerdelga Consumer Medicine Information. 2. Cerdelga Product Information. Cerdelga® is a registered trademark of Sanofi. sanofi-aventis australia pty ltd trading as Sanofi ABN 31 008 558 807. 12-24 Talavera Road, Macquarie Park, NSW 2113. MAT-AU-2200206-2.0. Date of preparation February 2024.

sanofi

PBS Information: This product is not listed on the PBS.

Please review full Product Information before prescribing, available by scanning the QR code, visiting <https://qr.medsinfo.com.au/tx/sw.cfm?h=swccerde> or by calling 1800 818 806.



Reference: 1. Cerdelga Australian Approved Product Information.

Cerdelga® is a registered trademark of Sanofi. sanofi-aventis australia pty ltd trading as Sanofi ABN 31 008 558 807. 12-24 Talavera Road, Macquarie Park, NSW 2113. MAT-AU-2200205-6.0. Date of preparation February 2024.